Ibrutinib „first line“ in der CLL-Therapie
Crossref DOI link: https://doi.org/10.1007/s15004-017-5870-x
Published Online: 2017-11-02
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mundt, Maren